Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

July 28, 2011

Primary Completion Date

May 8, 2012

Study Completion Date

May 8, 2012

Conditions
Hyperlipidemia
Interventions
BIOLOGICAL

Evolocumab

Administered by subcutaneous injection

DRUG

Ezetimibe

Administered orally once a day

OTHER

Placebo to Evolocumab

Administered by subcutaneous injection

Trial Locations (42)

1180

Research Site, Uccle

1200

Research Site, Brussels

2015

Research Site, Camperdown

2022

Research Site, Sydney

2750

Research Site, Ballerup Municipality

3004

Research Site, Melbourne

6000

Research Site, Perth

7100

Research Site, Vejle

10029

Research Site, New York

20815

Research Site, Chevy Chase

27609

Research Site, Raleigh

30338

Research Site, Atlanta

30342

Research Site, Atlanta

31406

Research Site, Savannah

37620

Research Site, Bristol

43204

Research Site, Reus

Research Site, Reus

44311

Research Site, Akron

45212

Research Site, Cincinnati

50009

Research Site, Zaragoza

Research Site, Zaragoza

59701

Research Site, Butte

89052

Research Site, Henderson

89117

Research Site, Las Vegas

90029

Research Site, OYS

91361

Research Site, Westlake Village

92691

Research Site, Mission Viejo

92801

Research Site, Anaheim

04210

Research Site, Auburn

A1A 3R5

Research Site, Saint John’s

Research Site, St. John's

H8S 2E4

Research Site, Lachine

00029

Research Site, Helsinki

08036

Research Site, Barcelona

Research Site, Barcelona

08907

Research Site, L'Hospitalet de Llobregat

Research Site, L'Hospitalet de Llobregat

411 36

Research Site, Göteborg

Research Site, Gothenburg

222 21

Research Site, Lund

111 35

Research Site, Stockholm

141 86

Research Site, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01375764 - Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects | Biotech Hunter | Biotech Hunter